⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463717 | 1.00 | — | — | |
| SCHEMBL12329241 | 1.00 | — | — | |
| SCHEMBL14747372 | 1.00 | — | — | |
| SCHEMBL18523022 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL18707465 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL18962605 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL16785937 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL22631740 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL21783260 | 0.92 | GBA1 (0.41) | — | |
| SCHEMBL13425150 | 0.92 | GBA1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863146-B | Biaryl compounds as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | claimed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | claimed |
| EP-2903617-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | claimed |
| WO-2014058685-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | claimed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | claimed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2000023447-B1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2000-06-29 | — | — | WO | claimed |
| CN-116715700-A | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113366008-B | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111094317-B | Phosphonic acid derivative with CD73 inhibitory activity, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-109863146-B | Biaryl compounds as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3134411-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | Vitae Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2903617-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014058685-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2535345-A1 | Anticancer nucleoside analogs | BioCryst Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-0475411-B1 | Novel carbocyclic adenosine analogs useful as immunosuppressants | AVENTIS PHARMA INC (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-0779885-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES CONTAINING A SUBSTITUTED BENZIMIDAZOLE BASE ATTACHED TO A CARBOCYCLIC RING | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007646-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES CONTAINING A SUBSTITUTED BENZIMIDAZOLE BASE ATTACHED TO A CARBOCYCLIC RING | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-14 | — | — | WO | disclosed |
| US-4704392-A | VIRICIDES | SYNTEX (U.S.A.) INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4605659-A | HERPES; HEPATITUS | SYNTEX (U.S.A.) INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4605659-A | HERPES; HEPATITUS | SYNTEX (U.S.A.) INC. (US) | 1986-08-12 | — | — | US | disclosed |